AC Immune SA is a clinical product company in Alzheimer's Disease located at the Parc Scientifique d'Ecublens (PSE) on the site of the EPFL in Lausanne, Switzerland.   AC Immune develops innovative therapeutics against Alzheimer's disease along three axes: vaccines, antibodies and small molecules. The products enter clinical trials in 2008/2009 and are backed by a rich portfolio of compounds at preclinical stage. Therapeutic molecules are leveraged for Alzheimer's disease diagnostic. AC Immune's drug pipeline will be further enhanced by leveraging its products in other conformational disorders.		Financing Round C and Key Appointments 26.01.2009 AC Immune Shapes its Future as World Economic Forum Technology Pioneer 2009 [UPDATED] More...   Technology Pioneer 2009 04.12.2008: Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer´s Disease More...   License Agreement with Genentech 07.12.2006: Exclusive Global License Agreement and Research Collaboration with Genentech More...